Background and Aims:
Anemia is a common complication of heart failure and
chronic kidney disease (CKD). Sacubitril-valsartan is a novel therapy for the
treatment of chronic heart failure with a reduced ejection fraction (HFrEF). We
have evaluated the short-term effects of sacubitril-valsartan on the anemia of
CRS.
Methods:
The study group comprised 39 patients with HFrEF, who were
followed-up for three months. The study is a retrospective analysis of clinical
data. Data of 3 months’ visit and baseline visit were recorded including:
plasmatic creatinine, glomerular filtration rate, cystatin C, kaliemia,
haemoglobin, pro-BNP and albuminuria.
Results:
In all, 34 patients ended the follow-up. Mean sacubitril-valsartan dosage
at baseline was 101±62 mg/day and 126±59 mg/day at end. Mean hemoglobin
increased from 12.2±1.1 g/dl at baseline to 12.9±1.0 g/dl (p = 0.001,). Prevalence of
anemia was 64.7% (95%CI,47.9-78.5%) at baseline and 38.4 (95%CI,23.9-55.0%)
after the follow-up (p = 0.016). Serum cystatin C levels decreased from 2.71±1.0
to 2.48±1.0 mg/l (p = 0.028). Serum K levels remained unchanged (baseline
4.94±0.60, three months visit 4.94±0.61 mmol/l, p = 0.998).
Conclusions:
Sacubitril-valsartan improves anemia in CRS patients. An
improvement of serum cystatin levels was observed. Few untoward effects were
detected. These findings should be confirmed in wider clinical trials.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.